T he inositol 1,4,5-trisphosphate (IP 3 ) 4 -gated intracellular Ca 2ϩ release, resulting from the activation of receptor tyrosine kinases and G protein-coupled receptors, is an important regulator of various cellular processes, including proliferation and apoptosis (1) (2) (3) (4) (5) (6) (7) . Several endogenous and exogenous activators of IP 3 R1 have been reported, including phosphorylation, positive and negative feedback by Ca 2ϩ , and association with other accessory molecules (3, 8 -17) . However, the precise mechanism by which phosphorylation via specific kinases modulates IP 3 R function remains unknown; moreover, the significance of this modulation in the context of cell survival is unclear.
In a previous study, we reported that a cell cycle-dependent kinase, cdc2, phosphorylates IP 3 R1 in vitro and in vivo (3) . This observation is consistent with previous reports that IP 3 -gated calcium release is modulated during the cell cycle (18 -20) . In the present study, we show that cyclins/cyclin-dependent kinases (cdks) directly interact with and modulate IP 3 -gated Ca 2ϩ release via phosphorylation. In addition, we report that cyclin B1 (CyB1) interacts directly with IP 3 R1 through cyclin-binding motifs. These results provide a novel mechanism by which cyclins/cdks regulate IP 3 -gated Ca 2ϩ release during cell cycle progression.
Materials and Methods

Animals
Rats were obtained from Sprague-Dawley and maintained in a pathogenfree facility of the St. Luke's Roosevelt Hospital Center. The facility is fully accredited by the American Association for Accreditation of Laboratory Animal Care.
Cell culture and reagents
Jurkat cells (human leukemic T cell line, clone E6.1; American Type Culture Collection) were cultured in RPMI 1640 medium containing 10% FCS and 100 U/ml penicillin and streptomycin. The cells were split every 2 days to maintain log-phase growth. Antiserum to IP 3 R1, raised against a synthetic peptide of the human IP 3 R1 sequence (aa 1829 -1848), was purchased from Alexis Biochemicals. In some experiments, anti-IP 3 R1 was also used (a gift from G. Mignery, Loyola University, Chicago, IL) (21) . The p13-Suc-1-agarose beads and mAb to cdc2 were obtained from Oncogene Biosciences, and the protease inhibitor mixture was from SigmaAldrich. The cdc2/CyB and PHA were obtained from Calbiochem.
Spleen cell preparation and stimulation
Spleen cells were harvested from Sprague-Dawley rats and were stimulated with and without PHA for 24 h. Uninduced and PHA-induced cells were lysed in lysis buffer (50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 1 mM EDTA, 0.1 mM NaF, 1 mM Na 3 VO 4 , 10 mM ␤-glycerophosphate, 1 mM DTT, 0.5 mM PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin, 10 g/ml soybean trypsin inhibitor, and 0.5% Nonidet P-40 (v/v)). Immunoprecipitation was performed using these lysates and anti-IP 3 R1 Ab, followed by immunoblotting with Abs against IP 3 R1, cdc2, and CyB, as described (8) .
Generation of phosphospecific Abs to IP 3 R1
Polyclonal Abs were raised in rabbits against two phosphopeptide sequences (MLKIGTS*PVKEDKEA and DPQEQVT*PVKYARL) within murine IP 3 R1 that contain the Ser 421 and Thr 799 phosphorylation residues, respectively. The polyclonal Abs were affinity purified with two cycles of purification by initially passing through nonphosphorylated peptides and then the appropriate phosphorylated peptides. The titer and specificity of the phosphospecific Abs were determined by ELISA and immunoblotting.
Western blotting, immunoprecipitation, and in vitro kinase reactions
Cell numbers were calculated, equalized across treatment groups, and lysed in ice-cold lysis buffer containing 0.5% Nonidet P-40, 25 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , and protease inhibitors. Cell lysates were centrifuged at 13,000 ϫ g in a microcentrifuge, and the supernatants were subjected to immunoblotting and immunoprecipitation or incubation with Suc-1 coupled to agarose beads (22, 23) . The membranes were blocked in TBST (20 mM Tris-HCl (pH 7.4), 0.9% NaCl, and 0.05% Tween 20) containing 5% nonfat dried milk for 1 h, followed by incubation with primary Abs. After extensive washing, the membranes were incubated with their respective secondary Abs (goat anti-rabbit IgG, BD Pharmingen; or goat anti-mouse IgG, Santa Cruz Biotechnology) conjugated to HRP in TBST containing 5% nonfat dried milk. The immunoblots were analyzed using the ECL detection system (Amersham). Immunoprecipitations were performed with the anti-IP 3 R1 Ab, as described (8) , and the immune complexes were washed three times with ice-cold buffer containing 25 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM Na 3 VO 4 , 0.5% Nonidet P-40, and a mixture of protease inhibitors containing 4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A, E64, bestatin, leupeptin, and aprotinin (Sigma-Aldrich). The kinase assays were performed at 30°C for 10 min in 25 l of a solution containing 50 mM Tris (pH 7.4), 10 mM MgCl 2 , 1 mM DTT, and 10 Ci of [␥-
32 P]ATP with and without exogenous cdc2/CyB. Phosphoproteins were separated by SDS-PAGE and detected by autoradiography, as described (3, 8) .
Generation of wild-type and cdc2 phosphorylation-deficient mutant GST proteins and pull-down assays
Generation of pGEX constructions that encode GST fusion proteins and the purification of the expressed proteins have been described previously (24) . The regions corresponding to residues 375-473, 753-886, and 1-900 of mouse IP 3 R1 were amplified by PCR and cloned into the BamHI and EcoRI sites of pGEX2T (Amersham Biosciences). S421A and T799A mutations were introduced using the QuikChange mutagenesis kit (Stratagene), and mutations were confirmed by sequencing. GST fusion constructs containing residues 375-473 (IP 3 R1/375-473) and 753-886 (IP 3 R1/753-886) as well as the mutant constructs (S421A and T799A) were expressed in (Escherichia coli) JM101 (Stratagene). The proteins were induced from 15 ml of cell culture (A 600 ϭ 0.5) with 0.1 mM isopropyl-␤-D-thiogalactopyranoside at 37°C for IP 3 R1/375-473 and at 12°C for IP 3 R1/753-886 fusion proteins. Fusion proteins were purified on glutathione-agarose beads, per the manufacturer's instructions (Amersham Biosciences), and washed three times in PBS containing 1% Triton X-100 to remove nonspecifically bound proteins. For generating the cyclin binding-deficient IP 3 R1 mutants, we replaced arginine (R) in the cyclin-binding motif, RXL, with glycine (G). For the pull-down assays, wild-type and mutant proteins of fragments 375-473 and 753-886 were bound to sf-9-purified CyB1, washed extensively, and resolved on 10% SDS-PAGE gels.
Binding studies with Suc-1-agarose p13-Suc-1-agarose was incubated with cycling Jurkat cell lysates on ice for 2 h. The resin was washed three times in lysis buffer (20 mM Tris-HCl (pH 7.4), 1% Triton X-100, plus a mixture of protease inhibitors containing 4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A, E64, bestatin, leupeptin, and aprotinin). Proteins bound to the immobilized Suc-1 were released by boiling the agarose resin in SDS-PAGE sample buffer for 5 min, followed by separation via SDS-PAGE. The proteins were transferred to nitrocellulose and immunoblotted with their respective indicated Abs.
IP 3 -binding assay
The IP 3 -binding assay was performed using the IP 3 R1 (1-900) fragment, as described (3). The soluble protein (30 g) was incubated with 9.6 nM tritiated IP 3 in 100 l of binding buffer for 10 min at 4°C. The mixture was then added to 4 l of ␥-globulin (50 mg/ml) and 100 l of a solution containing 30% (w/v) polyethylene glycol 6000, 50 mM Tris-HCl (pH 8.0 at 4°C), 1 M 2-ME, and 1 mM EDTA. After incubation at 4°C for 5 min, the protein-polyethylene glycol complex was collected by centrifugation at 10,000 ϫ g for 5 min at 2°C. The pellets were dissolved in 180 l of Solvable (DuPont NEN). After neutralization with 18 l of acetic acid, the radioactivity was measured in 5 ml of Atomlight (DuPont NEN) with a liquid scintillation counter. The specific binding was calculated by subtracting the nonspecific binding (in the presence of 2 M IP 3 ) from the total binding measurement. 45 Ca release assay Rat brain microsomes were isolated according to Michikawa et al. (25) and then resuspended in 10% sucrose, 1 mM 2-ME, and 10 mM MOPS/TrisHCl (pH 7.0) (3.3 mg protein/ml), diluted with an equal volume of 300 mM KCl, and 2 l of 45 Ca (sp. act., 1.85 Gbq/mg; Amersham Biosciences) was then added. After incubation for 160 min on ice, the samples were adjusted to 2 mM MgCl 2 and 0.2 mM Na 2 ATP. The samples were incubated with 60 U/ml cdc2, 60 M roscovitine, or 5 M digitonin for 10 min at room temperature, and were then diluted with 3 vol of 150 mM KCl, 10 mM EGTA, and 20 mM Tris-HCl (pH 7.8). Ca 2ϩ release was induced by 1 M IP 3 , and was measured after 1 min by adding 6 l of stop solution (150 mM KCl, 10 mM EGTA, 20 mM Tris-HCl, and 1 mM La (pH 7.8)).
Results
In a previous study, we showed that cdc2 phosphorylates IP 3 R2 . To test whether other IP 3 R are also substrates for the cdc2/CyB complex, we immunoprecipitated IP 3 R1, 2, and 3 from Jurkat lymphocytes with subtype-specific Abs, incubated them with the cdc2/CyB complex, and size fractionated by SDS-PAGE. To confirm the sites of phosphorylation on the IP 3 R, we used our phosphospecific polyclonal Abs generated against two phosphopeptides (MLKIGTS*PVKEDKEA and DPQEQ VT*PVKYARL) that include the Ser 421 and Thr 799 phosphorylation sites (asterisks), respectively. The specificity of the affinitypurified phosphospecific Ser 421 and Thr 799 Abs was confirmed by dot-blot analysis using phosphorylated and nonphosphorylated peptides, as described (3). As shown in Fig. 1, A and B, the phosphospecific Abs, anti-Ser 421 and anti-Thr 799 , detected cdc2/CyBphosphorylated IP 3 R1 in immunoblot analysis. Although the antiThr 799 Ab also detected IP 3 R3-specific phosphorylation by the cdc2/CyB complex, neither of these Abs, however, detected phosphorylation of IP 3 R2 by cdc2/CyB. The absence of IP 3 R2 immunoreactivity to these Abs was not due to a paucity of IP 3 R2 in the immune complex (data not shown) as compared with IP 3 R1 (Fig.  1C) . Rather, these data collectively indicate that IP 3 R1 and 3 are specific phosphorylation substrates of the cdk1/CyB complex and that our phosphoantibodies recognize their respective phosphorylated epitopes within IP 3 R1.
We next investigated whether IP 3 R1 binds the cdc2/CyB complex in vivo. Cell lysates from cycling Jurkat cells were adsorbed to p13-Suc-1-agarose, and we assayed the bound proteins for the presence of IP 3 R1 and cdc2. p13-Suc-1 binds to selected cdk with high affinity and is frequently used in affinity-ligand searches for cdc2 (22, 23) . The presence of cdc2 on the p13-Suc-1-agarose was verified by immunoblotting with the anti-cdc2 Ab (Fig. 2B) ; moreover, the anti-IP 3 R1 Ab specifically recognized a protein of ϳ300 kDa that comigrated with IP 3 R1 during SDS-PAGE ( Fig. 2A) . Taken together, these data suggest that cdc2/CyB interacts directly or indirectly with IP 3 R1. To further examine the nature of the interaction between cdc2/CyB and IP 3 R1 during quiescent and proliferative cell stages, we analyzed immune complexes of IP 3 R1 from rat primary lymphocytes stimulated with and without PHA. PHA induces rapid proliferation of lymphocytes. IP 3 R1 immune complexes from the PHA-stimulated cells contained cdc2 and CyB, whereas the immune complexes from nonproliferating quiescent cells contained no detectable cdc2 or CyB, even though the IP 3 R1 level was equivalent to that in the PHA-stimulated population (Fig. 2, C-E) . These results indicate that IP 3 R1 interacts with cdc2/CyB1 in normal primary lymphocytes after activation and that the interaction does not occur in quiescent cells due to a lack of CyB1 expression at the G 0 /G 1 stages of the cell cycle (26) . Several studies have demonstrated the presence of cyclin-binding motifs (RXL) in target proteins, thereby facilitating cyclin/cdk/ target protein interactions (27, 28) . Our primary sequence analysis revealed three putative CyB-binding motifs ( 391 RHL, 441 RDL, and 871 RNL) in IP 3 R1 that are proximal to the cdc2 phosphorylation site(s). To investigate whether these sites are involved in the establishment of the CyB/cdc2/IP 3 R1 complex, we incubated GST fusion proteins encoding wild-type and mutant IP 3 R1 phosphorylation site fragments bound to glutathione-Sepharose with purified CyB and cdc2 proteins. Nonspecifically bound proteins were washed extensively, and the bound proteins were eluted, size fractionated, and probed with either anti-CyB1 or anti-cdc2 Abs in immunoblots. Although CyB1 interacted with both wild-type and phosphorylation-deficient IP 3 R1 fragments (375-473 and 753-886; Fig. 2F ), CyB1 bound very poorly to the same IP 3 R1 fragments, in which three of the arginine (R) residues in the CyBbinding motif, RXL, were changed to glycine (G) (Fig. 2F) . Taken together, these results suggest that CyB1 binding to IP 3 R1 is dependent on Arg 391 , Arg 441 , and Arg 871 . A previous study showed that the IP 3 -binding specificity of an N-terminal IP 3 R1 fragment expressed in E. coli is very similar to that of the native IP 3 R from mouse cerebellum (29) . We used a similar approach to investigate the functional effect of cdc2/CyBmediated phosphorylation of IP 3 R1 on IP 3 binding. For these studies, we constructed a GST fusion protein containing the first 900 N-terminal residues of IP 3 R1, IP 3 R1 (1-900), which encodes the IP 3 -binding pocket and the two cdc2/CyB phosphorylation sites. We induced protein expression in E. coli with isopropyl-␤-D-thiogalactopyranoside. Using this approach, we showed that cdc2 phosphorylation of this fusion protein increased IP 3 binding by 3-fold, which was attenuated by roscovitine (3). IP 3 binding to the S421A mutant was comparable to wild-type IP 3 R1. In contrast, the T799A mutation significantly reduced IP 3 binding ( p Ͻ 0.05). Mutation of both phosphorylation residue sites severely inhibited IP 3 binding and is highly significant ( p Ͻ 0.001) (Fig. 3A) . Thus, the data in Fig. 3A show that the lack of phosphorylation at both of these sites negatively impacts IP 3 binding. To determine the independent effect of cdc2/CyB-mediated phosphorylation at Ser 421 and Thr 799 on IP 3 binding, we used wild-type and phosphorylation-deficient IP 3 R1 mutants (1-900), in which these potential phosphorylation sites were changed to alanine. The IP 3 -binding experiments were performed with increasing concentrations of unlabeled cold IP 3 . Specific IP 3 binding is shown with wild-type (Fig. 3B), S421A (Fig. 3C) , T799A (Fig. 3D) , and S421A ϩ T799A mutants (Fig. 3E) . Our results show that IP 3 binding to the wild type is significantly increased upon phosphorylation by cdc2/CyB complex ( Fig. 3B ; p Ͻ 0.05). Although S421A mutation resulted in reduced IP 3 binding after phosphorylation as compared with wild-type IP 3 R1 (Fig. 3 , B and C; p Ͻ 0.05), T799A mutation completely abrogated the effect of phosphorylation on IP 3 binding ( Fig. 3D ; p Ͻ 0.05). Consistent with these findings, we also found that IP 3 binding is severely impaired in the phosphorylation-deficient double mutant, S421A ϩ T799A as compared with wild-type IP 3 R1 (Fig. 3 , B and E; p Ͻ 0.001).
We next measured IP 3 -induced Ca 2ϩ release from cerebellar microsomes with and without phosphorylation to determine whether cdc2/CyB phosphorylation of IP 3 R1 modulates this process. The phosphorylation of IP 3 R1 by the cdc2/CyB complex was performed, as shown in Fig. 3 . The microsomes were loaded with 45 Ca, and subsequent Ca 2ϩ release was triggered by activating IP 3 R with 1 M IP 3 . Although the IP 3 -induced Ca 2ϩ release in the control microsomes (without phosphorylation) was 34% of the total cellular Ca 2ϩ , the Ca 2ϩ release increased by 47% upon cdc2/ CyB-mediated phosphorylation (50% of the total Ca 2ϩ ), which was completely blocked by roscovitine (Fig. 4) .
Discussion
Our main findings are summarized as follows: 1) cdc2/CyB directly interacts with IP 3 R; 2) this interaction is mediated via Cy docking sites on the IP 3 R; 3) phosphorylation at Thr 799 significantly alters IP 3 binding; 4) phosphorylation increases IP 3 Because the phosphospecific Abs were directed against two consensus phosphorylation motifs on IP 3 R1, we cannot exclude the possibility that other potential sites may be weakly phosphorylated by the cdc2/CyB complex. Nevertheless, the fact that IP 3 R2 contains several Ser-Pro (S-P) or Thr-Pro (T-P) residues, but lacks a consensus phosphorylation motif and reactivity with these Abs, emphasizes the utility of these reagents to monitor the phosphorylation status of consensus IP 3 R sites in vivo.
Previous approaches used to determine cdc2/Cy-substrate interactions include p13-Suc-1 affinity columns, immunoprecipitation, and pull-down assays (22, 23) . To detect the IP 3 R1/cdc2/CyB complex, we used a cdc2 affinity resin, p13-Suc-1-agarose. Incubation of cell lysates with this Suc-1 resin yielded an additional protein other than cdc2 migrating at ϳ300 kDa that reacted with the anti-IP 3 R1 Ab. A lack of IP 3 R1 from lysates incubated with agarose beads alone suggests a specific association between IP 3 R1 and cdc2, although it is possible that a nonspecific interaction between IP 3 R1 and the Suc-1 resin could have occurred. However, this is unlikely because this association is observed only in proliferating lymphocytes after PHA stimulation and not in quiescent cells. Alternatively, lack of expression of CyB1 in quiescent cells could also have accounted for the absence of the IP 3 R1/CyB1/cdc2 complex (26) . The data suggest the latter possibility, and we propose that CyB1 expression is critical for its association with IP 3 R1. Moreover, the CyB1 interaction in normal lymphocytes also shows that the finding is not unique to transformed Jurkat cells, whose growth is less dependent on growth factors.
To further determine whether IP 3 R interact directly with CyB1, we exploited IP 3 R1 fragments containing putative cyclin binding and phosphorylation sites. We mixed these fragments with purified CyB1 and assessed binding. CyB1 binding to wild-type as well as phosphorylation-deficient mutants suggests that CyB1 interacts with IP 3 R1 at residues distal to the phosphorylation sites. The lack of CyB1 interaction with Cy binding-deficient mutants suggests that CyB1 binding to IP 3 R1 is dependent on Arg 391 , Arg 441 , and Arg 871 . Similar interactions between cyclins and target proteins via RXL motifs have been reported (27, 28, 30) . The finding that CyB1 interacts with IP 3 R1 suggests that it may have a role in regulating IP 3 R function during the cell cycle. For instance, CyB1 may target IP 3 R1 via a cyclin-specific interaction with its kinase partner and thereby influence the subcellular localization of phosphorylation (28) . Subcellular localization may alter spatio-dynamic calcium changes and keep complexes sequestered from improper substrates, or expose the complexes to activators or inhibitors that are localized to specific compartments (31, 32) . IP 3 binding is critical not only for the activation of IP 3 R channels, but also for their inactivation (16) . The N-terminal 734 residues of IP 3 R1 (T734) expressed in E. coli exhibited IP 3 -binding characteristics similar to those of the native cerebellar IP 3 R. Further analyses of the N-terminal 734 residues of IP 3 R1 showed that a 353-residue sequence (residues 226 -578) constitutes an IP 3 binding region. To determine the consequences of IP 3 R phosphorylation at specific sites, we generated phosphorylation-deficient mutants as GST fusion proteins to elucidate the effect of phosphorylation of IP 3 R proteins on IP 3 binding. Interestingly, significantly reduced IP 3 binding was measured for the T799A mutant; this threonine residue is conserved in IP 3 R1 and IP 3 R3. Thus, this phosphorylation at Thr 799 may induce a conformational change in these receptors that facilitates IP 3 binding. By contrast, the S421A mutation had a relatively minimal effect. Given that Ser 421 is within the IP 3 binding region, this result is contrary to our expectation that Ser 421 phosphorylation would modulate IP 3 binding due to conformational changes. These results suggest that cdc2 phosphorylation modulates Ca 2ϩ signaling through IP 3 binding and that phosphorylation at residue Thr 799 is critical for this function. Mutation analysis revealed that 10 basic residues scattered throughout this sequence are important for IP 3 binding and that these residues are conserved among all members of the IP 3 R family (29) . Of these 10 residues, three are critical, and one is known to be involved in IP 3 -binding specificity (33 The cdc2 phosphorylation increases Ca 2ϩ release. Microsomes from rat brain were isolated and resuspended in 10% sucrose, 1 mM 2-ME, and 10 mM MOPS/Tris (pH 7.0) (3.3 mg protein/ml), and diluted with an equal volume of KCl and with 45 Ca. After incubation of the samples for 160 min on ice, 2 mM MgCl 2 and 0.2 mM Na 2 ATP were added. The samples were incubated with various combinations of 60 U/ml cdc2, 60 M roscovitine, and 5 M digitonin for 10 min at room temperature. Ca 2ϩ release was induced by 1 M IP 3 and measured after 1 min. The data represent the mean Ϯ SD of three independent experiments. Each asterisk indicates a statistically significant (p Ͻ 0.05) difference in Ca 2ϩ release in the presence or absence of the cdc2/CyB complex. IP 3 R1 by cdc2/CyB complex. However, it is still possible that kinases other than cdc2/CyB may also modulate Ca 2ϩ mobilization during the cell cycle. For instance, cell cycle-dependent Ca 2ϩ changes may also be modulated via phosphorylation of IP 3 R by MAPK and/or Src kinases, which are active during the mitotic phase of the cell cycle. Protein phosphorylation is known to regulate numerous cellular functions, including apoptosis. Given that phosphorylation at Thr 799 is important for increasing the affinity of IP 3 R1 for IP 3 , the increased phosphorylation at Thr 799 after HIV infection suggests that HIV may selectively manipulate IP 3 -gated Ca 2ϩ signaling.
In this study, we demonstrated that cdc2 phosphorylation alters certain IP 3 R properties and increases IP 3 -gated Ca 2ϩ release. Given that cells deficient in IP 3 R fail to undergo activation-induced apoptosis (4, 6, 7) and that there is good correlation between increased cdc2/CyB activity and apoptosis in several human disorders, inappropriate and sustained phosphorylation of IP 3 R may result in higher cytoplasmic Ca 2ϩ concentrations that may be detrimental to cell survival (35) . This viewpoint is further supported by evidence that breast cancer resistance correlates with inactivation of cdc2/CyB activity (36, 37) . Indeed, our preliminary studies indicate that phosphorylation-deficient mutant cells are relatively resistant to activation-induced apoptosis (data not shown).
The identification of apoptosis as the mechanism of cell demise/ clearance under both normal physiological and pathological conditions has led to a growing interest in delineating the biochemical and molecular controls underlying this important process. For example, most self-reactive immature B cells having elevated cytoplasmic Ca 2ϩ undergo apoptosis during development (i.e., clonal deletion) to establish immunological tolerance (38 -40) , whereas HIV infection causes profound immunological defects in afflicted patients, with high levels of immune activation and apoptosis of CD4 ϩ T cells. The increased frequency of apoptosis of CD4 ϩ T cells in HIV patients and serious perturbations of the cell cycle are associated with increased CyB1 expression and p34 cdc2 activity (41) (42) (43) (44) (45) (46) (47) (48) . It is therefore likely that an abnormal relationship between T cell activation/proliferation and the occurrence of apoptosis may play a significant role in lymphocyte depletion in HIV patients. Syncytia (fusion of cells expressing the HIV-1-encoded Env gene with cells expressing the CD4/CXCR4 complex) occur upon sequential activation of CyB-cdk1, mammalian target of rapamycin, and p53; cdk1 inhibition by roscovitine/olomoucine prevents syncytial cell death elicited by HIV-1 infection of primary CD4 lymphoblasts (41) . The neurotoxin protein HIV-Tat activates IP 3 -gated calcium stores in conferring neuronal cell death, which in turn causes AIDS-related dementia complex (42) . HIV infection also causes IP 3 R1 to associate with the HIV-1 Nef protein, which promotes the early viral life cycle (43) (44) (45) . These findings suggest the possible involvement of IP 3 R-mediated Ca 2ϩ signaling in HIV pathogenesis. A detailed examination of IP 3 R phosphorylation pathway using blocking peptides may help to develop new strategies for treating HIV infection.
In summary, we present evidence that cdc2/CyB interacts with and phosphorylates IP 3 R, and that this phosphorylation increases Ca 2ϩ release by increasing the binding affinity of IP 3 for IP 3 R. The cdc2-mediated phosphorylation of IP 3 R, increased IP 3 binding, and IP 3 R-mediated intracellular Ca 2ϩ release are logical steps to explain the relationship between increased cdc2 activity and increased sensitivity to activation-induced apoptosis in many human disorders, including HIV. Because the cdc2/CyB complex is also necessary for the cell cycle, we suggest that other players, such as phosphatases and cy/cdk inhibitors, play an important role in regulating IP 3 R phosphorylation and the intracellular Ca 2ϩ transients during the G 2 /M transition. In Materials and Methods, in the first sentence under the heading Virus and infection, the designation of the virus type should be human RSV A strain, not A2 strain.
